Menu
Search
|

Menu

Close
X

GenMark Diagnostics Inc GNMK.OQ (NASDAQ Stock Exchange Global Market)

6.27 USD
+0.03 (+0.48%)
As of Jul 17
Previous Close 6.24
Open 6.26
Volume 85,137
3m Avg Volume 86,723
Today’s High 6.35
Today’s Low 6.24
52 Week High 8.81
52 Week Low 3.58
Shares Outstanding (mil) 57.03
Market Capitalization (mil) 355.86
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
22
FY18
71
FY17
53
FY16
49
EPS (USD)
FY19
-0.213
FY18
-0.907
FY17
-1.217
FY16
-1.149
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.16
Price to Sales (TTM)
vs sector
4.97
8.16
Price to Book (MRQ)
vs sector
14.56
4.38
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
195.69
18.17
LT Debt to Equity (MRQ)
vs sector
195.69
13.01
Return on Investment (TTM)
vs sector
-64.18
12.64
Return on Equity (TTM)
vs sector
-117.61
17.19

EXECUTIVE LEADERSHIP

James Fox
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Hany Massarany
President, Chief Executive Officer, Director, Since 2011
Salary: $512,106.00
Bonus: --
Johnny Ek
Chief Financial Officer, Since 2019
Salary: --
Bonus: --
Scott Mendel
Chief Operating Officer, Since 2019
Salary: $354,400.00
Bonus: --
Eric Stier
Senior Vice President, General Counsel, Secretary, Since 2013
Salary: $244,531.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

5964 La Place Ct
CARLSBAD   CA   92008-8829

Phone: +1760.4484300

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.

SPONSORED STORIES